United States· US:72789-587_596c1dd8-1c45-cce6-e063-6394a90abe9a
Acyclovir
A aciclovir product containing acyclovir, registered in United States by PD-Rx Pharmaceuticals, Inc.. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Aciclovir is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AB01 (aciclovir), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Aciclovir · ATC J05AB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aciclovir costs, country by country.
Normalised to the WHO defined daily dose (4 g), the median price runs from $4.07 in Italy to $13.83 in Switzerland — a ×3.4 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Aciclovir · price per daily dose (4 g)
USD · FX 28 Sept 2026
- CH Switzerland$13.83
- IT Italy$4.07
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ACYCLOVIR
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- J05AB01
- ATC class
- Aciclovir
- Defined daily dose
- 4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 3
- ndc1172789-587-15
- ndc1172789-587-30
- ndc1172789-587-60
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
560 interactions on record for aciclovir.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aciclovir · interactions on record
560 records
- 19 severe
- 27 moderate
- 7 minor
- 505 info
Most severe, free to view
- CidofovirJ05AB12severe
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AB01
Aciclovir, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0973053-39f6-4a62-9ad9-5bc0d1c28663 GET /v1/drugs/c0973053-39f6-4a62-9ad9-5bc0d1c28663?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "400",
"substance": "ACYCLOVIR",
"productndc": "72789-587",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA210401",
"marketing_category": "ANDA"
}See everything about aciclovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.